

**INTERNAL INFORMATION ON FACTS AND CIRCUMSTANCES THAT TOOK  
PLACE IN THE SECOND QUARTER OF 2022  
TCHAIKAPHARMA HIGH QUALITY MEDICINES INC.**

- 1.1. There were no changes of the persons exercising control over the Company.
- 1.2. There were no insolvency proceedings against the company and all material stages, connected with such proceedings.
- 1.3. There were no essential contracts concluded or executed.
- 1.4. There was no decision on the conclusion, termination and rescission of a contract for joint venture.
- 1.5. Changes in the auditors of the Company – At a general meeting of shareholders held on 20.06.2022, a registered auditor was elected to review and certify the Annual Financial Statements of the parent company for 2022, namely Todor Krastev Stoyanov, Reg. No. 155.
- 1.6. There was no initiation or termination of legal or arbitration proceedings related to liabilities or receivables of the Company or its subsidiary, with claims of at least 10 percent of the company's equity.
- 1.7. There was no purchase, sale or pledge of shareholdings in commercial companies by the issuer or its subsidiary.
- 1.8. There are no circumstances that the Company believes may be relevant to investors in making a decision to acquire, sell or continue to hold publicly offered securities.

TCHAIKAPHARMA HIGH QUALITY MEDICINES INC. notifies all concerned parties that the Interim Financial Report of the Company as of the 30<sup>th</sup> of June 2022 was not certified by a registered auditor.



---

Biser Georgiev  
Executive Director